Bucking the Trend, Top Hedge Fund Makes Plans for a Second SPAC

Life sciences firm Cormorant, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company.

Stephen Taub January 25, 2024

Getty images

SPACs aren't dead. At least not to the folks at Cormorant Asset Management. Last week, the life sciences and biopharma specialist filed plans to raise $100 million for Helix Acquisition II, its second special purpose acquisition company. “All companies coming public will go up or

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login